Dennis C. Turk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dennis C. Turk has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
James P. Robinson
Department of Rehabilitation Medicine, Outcomes Research, Bethesda, Maryland
6 shared publicationsAkiko Okifuji
University of Utah
3 shared publicationsBob A. Rappaport
United States Food and Drug Administration, Silver Spring, MD, USA
3 shared publicationsJames Witter
United States Food and Drug Administration, now at United States National Institutes of Health, USA
3 shared publicationsJohn T. Farrar
Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
3 shared publicationsLaurie B. Burke
United States Food and Drug Administration, Silver Spring, MD, USA
3 shared publications
Latest Publications
- Open Access
- 18 January 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (7) , 1935-1956
Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations
Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.
- 18 January 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (7) , 1935-1956
Open AccessResearch design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations
Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.
- 1 May 2015
- Published by Elsevier in The Journal of Pain
- Vol. 16 (5) , 389-411
Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic Review
- 1 May 2015
- Published by Elsevier in The Journal of Pain
- Vol. 16 (5) , 389-411
Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic Review
- Open Access
- 30 April 2015
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 16 (7) , 1311-1324
Attitudes and Beliefs of Working and Work-Disabled People with Chronic Pain Prescribed Long-Term Opioids
Objective. This study was designed to gain insight into the apparent contradiction between the perspectives of researchers and policy makers, who have
- 30 April 2015
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 16 (7) , 1311-1324
Open AccessAttitudes and Beliefs of Working and Work-Disabled People with Chronic Pain Prescribed Long-Term Opioids
Objective. This study was designed to gain insight into the apparent contradiction between the perspectives of researchers and policy makers, who have
- 28 April 2015
- Published by Springer Nature in Journal of Rational-Emotive & Cognitive-Behavior Therapy
- Vol. 33 (3) , 218-238
Behavioral and Cognitive–Behavioral Approaches to Treating Patients with Chronic Pain: Thinking Outside the Pill Box
- 28 April 2015
- Published by Springer Nature in Journal of Rational-Emotive & Cognitive-Behavior Therapy
- Vol. 33 (3) , 218-238
Behavioral and Cognitive–Behavioral Approaches to Treating Patients with Chronic Pain: Thinking Outside the Pill Box
- Open Access
- 26 December 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set
Low back pain (LBP) is one of the most disabling and costly disorders affecting modern society, and approximately 90% of patients are labelled as having non-specific LBP (NSLBP). Several interventions for patients with NSLBP have been assessed in clinical trials, but heterogeneous reporting of outcomes in these trials has hindered comparison of results and performance of meta-analyses. Moreover, there is a risk of selective outcome reporting bias. To address these issues, the development of a core outcome set (COS) that should be measured in all clinical trials for a specific health condition has been recommended. A standardized set of outcomes for LBP was proposed in 1998, however, with evolution in COS development methodology, new instruments, interventions, and understanding of measurement properties, it is appropriate to update that proposal. This protocol describes the methods used in the initial step in developing a COS for NSLBP, namely, establishing a core domain set that should be measured in all clinical trials. An International Steering Committee including researchers, clinicians, and patient representatives from four continents was formed to guide the development of this COS. The approach of initiatives like Core Outcome Measures in Effectiveness Trials (COMET) and Outcome Measures in Rheumatology (OMERACT) was followed. Participants were invited to participate in a Delphi study aimed at generating a consensus-based core domain set for NSLBP. A list of potential core domains was drafted and presented to the Delphi participants who were asked to judge which domains were core. Participant suggestions about overlap, aggregation, or addition of potential core domains were addressed during the study. The patients’ responses were isolated to assess whether there was substantial disagreement with the rest of the Delphi panel. A priori thresholds for consensus were established before each Delphi round. All participants’ responses were analysed from a quantitative and qualitative perspective to ascertain that no substantial discrepancies between the two approaches emerged. We present the initial step in developing a COS for NSLBP. The next step will be to determine which measurement instruments adequately cover the domains.
- 26 December 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Open AccessA core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set
Low back pain (LBP) is one of the most disabling and costly disorders affecting modern society, and approximately 90% of patients are labelled as having non-specific LBP (NSLBP). Several interventions for patients with NSLBP have been assessed in clinical trials, but heterogeneous reporting of outcomes in these trials has hindered comparison of results and performance of meta-analyses. Moreover, there is a risk of selective outcome reporting bias. To address these issues, the development of a core outcome set (COS) that should be measured in all clinical trials for a specific health condition has been recommended. A standardized set of outcomes for LBP was proposed in 1998, however, with evolution in COS development methodology, new instruments, interventions, and understanding of measurement properties, it is appropriate to update that proposal. This protocol describes the methods used in the initial step in developing a COS for NSLBP, namely, establishing a core domain set that should be measured in all clinical trials. An International Steering Committee including researchers, clinicians, and patient representatives from four continents was formed to guide the development of this COS. The approach of initiatives like Core Outcome Measures in Effectiveness Trials (COMET) and Outcome Measures in Rheumatology (OMERACT) was followed. Participants were invited to participate in a Delphi study aimed at generating a consensus-based core domain set for NSLBP. A list of potential core domains was drafted and presented to the Delphi participants who were asked to judge which domains were core. Participant suggestions about overlap, aggregation, or addition of potential core domains were addressed during the study. The patients’ responses were isolated to assess whether there was substantial disagreement with the rest of the Delphi panel. A priori thresholds for consensus were established before each Delphi round. All participants’ responses were analysed from a quantitative and qualitative perspective to ascertain that no substantial discrepancies between the two approaches emerged. We present the initial step in developing a COS for NSLBP. The next step will be to determine which measurement instruments adequately cover the domains.
- 12 April 2014
- Published by Springer Nature
- p. 341-363
The Biopsychosocial Approach to the Assessment and Intervention for People with Musculoskeletal Disorders
- 12 April 2014
- Published by Springer Nature
- p. 341-363
The Biopsychosocial Approach to the Assessment and Intervention for People with Musculoskeletal Disorders
- 1 October 2013
- Published by Wolters Kluwer Health in Pain
- Vol. 154 (10) , 2235-2237
Cure by Fiat?
- 1 January 2013
- Published by Springer Nature
- p. 3244-3248
Psychological [Behavioral Health] Assessment of Pain
- 1 January 2013
- Published by Springer Nature
- p. 3244-3248
Psychological [Behavioral Health] Assessment of Pain
- 1 January 2013
- Published by Springer Nature
- p. 1927-1931
Multidisciplinary Pain Centers, Rehabilitation
- 1 January 2013
- Published by Springer Nature
- p. 1927-1931
Multidisciplinary Pain Centers, Rehabilitation
- 1 January 2013
- Published by Springer Nature
- p. 1923-1926
Multiaxial Assessment of Pain